These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

622 related items for PubMed ID: 30923985

  • 1. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
    Dulai PS, Osterman MT, Lasch K, Cao C, Riaz F, Sandborn WJ.
    Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
    [Abstract] [Full Text] [Related]

  • 2. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY.
    Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, Umashankar K, Rubin DT.
    Inflamm Bowel Dis; 2024 Oct 03; 30(10):1776-1787. PubMed ID: 37921344
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY.
    Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, Umashankar K, Rubin DT.
    BMC Gastroenterol; 2024 Sep 17; 24(1):314. PubMed ID: 39289603
    [Abstract] [Full Text] [Related]

  • 4. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
    Jensen KJ, Jensen CB, Wennerström C, Burisch J, Petersen J.
    Scand J Gastroenterol; 2023 Jul 17; 58(7):726-736. PubMed ID: 36802972
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Alulis S, Vadstrup K, Borsi A, Nielsen A, Rikke Jørgensen T, Qvist N, Munkholm P.
    Scand J Gastroenterol; 2020 Mar 17; 55(3):265-271. PubMed ID: 32116064
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States.
    Milev S, DiBonaventura MD, Quon P, Wern Goh J, Bourret J, Peeples-Lamirande K, Soonasra A, Cappelleri JC, Quirk D.
    J Med Econ; 2019 Sep 17; 22(9):859-868. PubMed ID: 31012362
    [Abstract] [Full Text] [Related]

  • 12. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease.
    Brady JE, Stott-Miller M, Mu G, Perera S.
    Clin Ther; 2018 Sep 17; 40(9):1509-1521.e5. PubMed ID: 30126706
    [Abstract] [Full Text] [Related]

  • 13. Factors Associated with Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel Disease.
    Abadir A, Troia A, Said H, Tarugu S, Billingsley BC, Sairam N, Minchenberg SB, Owings AH, Parker AM, Brousse B, Carlyle A, Owens BR, Hosseini-Carroll P, Galeas-Pena M, Frasca J, Glover SC, Papamichael K, Cheifetz AS.
    Dig Dis Sci; 2024 Aug 17; 69(8):2796-2803. PubMed ID: 38963462
    [Abstract] [Full Text] [Related]

  • 14. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
    Almario CV, Keller MS, Chen M, Lasch K, Ursos L, Shklovskaya J, Melmed GY, Spiegel BMR.
    Am J Gastroenterol; 2018 Jan 17; 113(1):58-71. PubMed ID: 29206816
    [Abstract] [Full Text] [Related]

  • 15. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
    Shaffer SR, Huang E, Patel S, Rubin DT.
    Am J Gastroenterol; 2021 Jan 01; 116(1):125-133. PubMed ID: 32947317
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS, Han M, Park S, Cheon JH.
    Dig Dis Sci; 2020 May 01; 65(5):1436-1444. PubMed ID: 31677070
    [Abstract] [Full Text] [Related]

  • 20. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Kobayashi T, Hoshi M, Yuasa A, Arai S, Ikeda M, Matsuda H, Kim SW, Hibi T.
    Pharmacoeconomics; 2023 May 01; 41(5):589-604. PubMed ID: 36884164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.